(19)
(11) EP 4 122 451 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
30.08.2023 Bulletin 2023/35

(43) Date of publication:
25.01.2023 Bulletin 2023/04

(21) Application number: 22190665.4

(22) Date of filing: 31.08.2011
(51) International Patent Classification (IPC): 
A61K 9/127(2006.01)
A61P 31/04(2006.01)
A61P 31/12(2006.01)
A61P 37/04(2006.01)
A61K 9/00(2006.01)
A61K 39/00(2006.01)
A61P 31/10(2006.01)
A61P 33/00(2006.01)
C12N 15/88(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0019; A61K 9/1271; A61K 9/1272; A61K 9/1277; A61K 39/00; A61K 2039/53; A61K 2039/55555; C12N 15/88; C12N 2710/16134; C12N 2760/18534; C12N 2770/36143; C12N 2770/36171; A61K 9/127; A61P 31/04; A61P 31/10; A61P 31/12; A61P 33/00; A61P 37/04
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 31.08.2010 US 37883110 P

(60) Divisional application:
23179893.5 / 4233841

(62) Application number of the earlier application in accordance with Art. 76 EPC:
21208092.3 / 4008357
11755497.2 / 2611467

(71) Applicant: GlaxoSmithKline Biologicals SA
1330 Rixensart (BE)

(72) Inventors:
  • GEALL, Andrew
    Emeryville, CA 94662-8097 (US)
  • VERMA, Ayush
    Emeryville, CA 94662-8097 (US)

(74) Representative: West, Heloise 
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)

 
Remarks:
This application was filed on 16.08.2022 as a divisional application to the application mentioned under INID code 62.
 


(54) SMALL LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA


(57) Nucleic acid immunisation is achieved by delivering RNA encapsulated within a liposome. The RNA encodes an immunogen of interest, and the liposome has a diameter in the range of 60-180nm, and ideally in the range 80-160nm. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer has a diameter in the range of 60-180nm; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.